Management of Elevated WBC and Platelets with Mild Neutrophilia and Thrombocytosis

Initial Diagnostic Approach

The American Society of Hematology recommends examining the blood smear carefully for morphologic clues that distinguish reactive from clonal processes, looking specifically for teardrop erythrocytes, large/giant platelets, granulocytic left shift with dysplasia, or toxic changes in neutrophils such as vacuolization 2
If neutrophils show vacuolization, this represents a medical emergency requiring immediate blood cultures and empiric antibiotics, as vacuolated neutrophils indicate active bacterial infection, sepsis, or severe systemic inflammation with high mortality risk 3

The European Society for Medical Oncology suspects primary bone marrow disorder (MPN) if any of the following are present: WBC count >100,000/mm³, concurrent unexplained anemia or abnormal red blood cell indices, splenomegaly or hepatomegaly on examination, constitutional symptoms, history of thrombosis at young age, or persistent elevations without identifiable reactive cause 1
Essential thrombocythemia (ET) and polycythemia vera (PV) are the most likely MPNs when both platelets and WBC are elevated with neutrophilia, as these conditions frequently present with thrombocytosis and leukocytosis together 1

The International Society on Thrombosis and Haemostasis recommends obtaining complete blood count with manual differential to determine absolute neutrophil count, assess for left shift, evaluate red blood cell indices, and confirm platelet count elevation 2
The National Comprehensive Cancer Network orders JAK2 V617F mutation testing immediately if MPN is suspected, as more than 95% of polycythemia vera patients and approximately 50-60% of essential thrombocythemia patients harbor this mutation 1

The American Society of Hematology recommends stratifying thrombotic risk immediately: high-risk patients include those age >60 years or with prior thrombosis history; low-risk patients are age ≤60 years with no thrombosis history 1, 4
The European Society for Medical Oncology recommends all high-risk patients require cytoreductive therapy with hydroxyurea as first-line treatment, starting at 15 mg/kg/day orally with dose adjustments to maintain platelet count <400,000/μL and WBC 4,000-10,000/μL 1
The American Journal of Hematology recommends adding low-dose aspirin 81-100 mg daily for all high-risk patients unless contraindicated by extreme thrombocytosis with acquired von Willebrand syndrome or active bleeding 1, 4

The National Comprehensive Cancer Network recommends checking complete blood count weekly initially until target counts achieved, then every 2-4 weeks during maintenance 1
The European Society for Medical Oncology recommends reducing hydroxyurea dose by 50% in patients with creatinine clearance <60 mL/min or end-stage renal disease, with close hematologic monitoring, although this is not directly cited, monitoring for hydroxyurea resistance or intolerance is defined as failure to achieve platelet count <400,000/μL and WBC <10,000/μL after 3 months of at least 2 g/day 1